Clinical Trials Logo

Filter by:
NCT ID: NCT01157858 Completed - Clinical trials for Polycystic Liver Disease

Everolimus and LongActing Octreotide Trial in Polycystic Livers

ELATE
Start date: June 2010
Phase: Phase 2
Study type: Interventional

The aim of this study is to reduce polycystic liver volume by treating with octreotide, whether or not combined with everolimus; to assess whether combination therapy of everolimus and octreotide gives a bigger reduction of polycystic liver volume than octreotide monotherapy.

NCT ID: NCT01157377 Completed - Clinical trials for Urinary Bladder, Overactive

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Start date: October 2010
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.

NCT ID: NCT01156844 Completed - Persistent Asthma Clinical Trials

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

Start date: March 2010
Phase: Phase 2
Study type: Interventional

This study assessed the bronchodilator efficacy of three different regimens of indacaterol in patients with asthma

NCT ID: NCT01156831 Completed - Clinical trials for Esophageal Neoplasms

PET-CT Based Radiotherapy in Esophageal Cancer Patients

Start date: November 2007
Phase: N/A
Study type: Observational

The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.

NCT ID: NCT01155778 Completed - Clinical trials for Mucopolysaccharidosis (MPS)

Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients

Start date: June 1, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Sanfilippo syndrome, or Mucopolysaccharidosis (MPS) III, is a rare lysosomal storage disease (LSD) caused by loss in activity of 1 of 4 enzymes necessary for degradation of the glycosaminoglycan (GAG) heparan sulfate (HS) in lysosomes. MPS IIIA results from deficiency of the enzyme heparan N-sulfatase (sulfamidase). MPS IIIA symptoms arise on average at 7 months of age, with the average age of diagnosis at 4.5 years for the majority of patients. The central nervous system (CNS) is the most severely affected organ system in patients with MPS IIIA, evidenced by deficits in language development, motor skills, and intellectual development. In addition, there are abnormal behaviors including but not limited to aggression and excess motor activity/hyperactivity that contribute to disturbances in sleep.Overall, individuals with MPS IIIA have a marked developmental delay and significantly reduced lifespan of 15 years of age on average. The purpose of this study is to determine the safety and tolerability of rhHNS via ascending doses administered via an a surgically implanted intrathecal drug delivery device (IDDD) intrathecal (IT) route once monthly (or every two weeks) for 6 months in patients with MPS IIIA.

NCT ID: NCT01155661 Completed - Clinical trials for Depressive Disorder, Major

A Safety Study in Participants With Major Depressive Disorder

Start date: October 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in participants with major depressive disorder (MDD) who are partial responders to their SSRI treatment.

NCT ID: NCT01154634 Completed - Reflux Clinical Trials

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.

NCT ID: NCT01154140 Completed - Clinical trials for Non Squamous Lung Cancer

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

PROFILE 1014
Start date: January 13, 2011
Phase: Phase 3
Study type: Interventional

This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.

NCT ID: NCT01153932 Completed - Clinical trials for Muscular Dystrophies

Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Start date: September 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether GSK2402968 given as a continuous dose and as an intermittent dose is effective and safe in the treatment of Duchenne muscular dystrophy.

NCT ID: NCT01153867 Completed - Clinical trials for Chronic Major Depressive Disorder

Schema Focused Therapy for Chronic Depression

Start date: January 2011
Phase: N/A
Study type: Interventional

Schema focused therapy (SFT) is an innovative treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. This study will determine whether SFT is a suitable and effective treatment for chronic depression in terms of acute effects and the prevention of relapse/recurrence. The secondary aim of this study is to identify the underlying mechanisms of change in SFT that lead to recovery from depression and the prevention of future relapse/recurrence.